Actively Recruiting
OnabotulinumtoxinA for Trigeminal Neuralgia
Led by Stanford University · Updated on 2026-01-22
20
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.
CONDITIONS
Official Title
OnabotulinumtoxinA for Trigeminal Neuralgia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women age 18 or older
- Legally competent to consent
- Sufficient knowledge of written and spoken English
- Able to attend regular in-person visits
- Failed, not a candidate for, or do not want surgery
- Inadequate response to at least two medication trials
- Meet ICHD criteria for Classical Trigeminal Neuralgia 13.1.1.1
- Experience more than 10 trigeminal neuralgia attacks per week
- Stable medication dose for at least the past 2 weeks
You will not qualify if you...
- Secondary or idiopathic trigeminal neuralgia or painful trigeminal neuropathy as defined by ICHD 13.1.1.2, 13.1.1.3, 13.1.2
- Pregnant or breastfeeding
- Have neuromuscular disease
- Currently taking aminoglycoside antibiotics
- Enrolled in any other clinical studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Meredith Barad
Stanford, California, United States, 94304
Actively Recruiting
Research Team
M
Meredith Barad, MD
CONTACT
N
Natali Ariyoshi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here